AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Check for active clinical trials using this agent.
1. Li X, Wang Y, Wang J, Zhang T, Zheng L, Yang Z, Xing L, Yu J.,Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.Int J Cancer. 2018 Jul 1;143(1):212-224. doi: 10.1002/ijc.31303. Epub 2018 Mar 1.
2. Chao D, Pang L, Shi Y, Wang W, Liu K., AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop.Biochem Biophys Res Commun. 2019 Feb 5;509(2):535-540. doi: 10.1016/j.bbrc.2018.12.102. Epub 2018 Dec 28.
Sun-shine Bio-tech provides a wide range of research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs, building blocks and Natural compounds for laboratory and scientific use.